Table 3.
Factors associated with antimicrobial resistance to CLR, AMX, MTZ, and LEV.
| Factors | Overall | CLR-R | p | AMX-R | p | MTZ-R | p | LEV-R | p |
|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | ||||||
| Age | |||||||||
| 5–10 years | 119 | 92 (77.3%) | 0.20 | 66 (55.5%) | 0.00 | 58 (48.9%) | 0.85 | 56 (47.1%) | 0.55 |
| 11–16 years | 118 | 99 (83.9%) | 104 (88.1%) | 59 (50.0%) | 51 (43.2%) | ||||
| Gender | |||||||||
| Male | 116 | 94 (81.0%) | 0.87 | 92 (79.3%) | 0.01 | 57 (49.1%) | 0.95 | 49 (42.2%) | 0.38 |
| Female | 121 | 97(80.2%) | 78 (64.5%) | 60 (49.6%) | 58 (47.9%) | ||||
| Prior treatment | |||||||||
| No | 183 | 141 (77.0%) | 0.01 | 127 (69.4%) | 0.14 | 94 (51.4%) | 0.26 | 76 (41.5%) | 0.39 |
| Yes | 54 | 50 (92.6%) | 43 (79.6%) | 23 (42.6) | 31 (57.4%) | ||||
| EGD Findings | |||||||||
| Nodular Gastritis | 164 | 127 (77.4%) | 0.66 | 107 (65.2%) | 0.00 | 76 (46.3%) | 0.58 | 80 (48.8%) | 0.79 |
| Peptic ulcer | 73 | 64 (87.7%) | 63 (86.3%) | 31 (42.5%) | 37 (50.7%) |
CLR-R, clarithromycin-resistant; AMX-R, amoxicillin-resistant; MTZ-R, metronidazole-resistant; LEV-R, levofloxacin-resistant; TET-R, tetracycline-resistant.